Consistent with the tumor size findings, the elevation of serum PSA levels in the anti-PSMA Ab-combined NK cell therapy group was delayed compared to that in the control and NK cell monotherapy groups during the observation period between days 10 and 22; the PSA level in the combined therapy group started to dramatically decrease after day 22 (Figure 6D). The gene discussed is KLK3; the disease is neoplasm.